BioSenic S.A. (EBR:BIOS)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.0025
-0.0001 (-3.85%)
At close: Feb 27, 2026
-26.47%
Market Cap 1.63M
Revenue (ttm) -2.39M
Net Income (ttm) -4.00M
Shares Out 652.86M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 970,320
Average Volume 1,427,219
Open 0.0026
Previous Close 0.0026
Day's Range 0.0025 - 0.0026
52-Week Range 0.0012 - 0.0035
Beta -2.29
RSI 55.72
Earnings Date Apr 24, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Jean-Luc Vandebroek
Employees 7
Stock Exchange Euronext Brussels
Ticker Symbol BIOS
Full Company Profile

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Financial Statements

News

There is no news available yet.